Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

Apr. 30 - Q1 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-03-14	10.07 $	+3.81%	711,370
25-03-13	9.700 $	-6.82%	886,205
25-03-12	10.41 $	+1.56%	1,736,403
25-03-11	10.25 $	+6.77%	1,387,873
25-03-10	9.600 $	-5.70%	1,181,757

Delayed Quote Nasdaq, March 14, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.07USD

Average target price

18.01USD

Spread / Average Target

+78.81%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-03-14 pm EDT			5-day change	1st Jan Change
10.07 ^USD	+3.81%		-1.08%	-26.55%

Mar. 12	Sector Update: Health Care Stocks Lower Late Afternoon	MT
Mar. 12	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT

Capitalization	919M 845M 814M 712M 1.32B 79.95B 1.46B 9.33B 3.53B 33.72B 3.45B 3.38B 136B	P/E ratio 2025 *	-12x	P/E ratio 2026 *	-22.6x
Enterprise value	903M 830M 799M 699M 1.3B 78.48B 1.43B 9.15B 3.47B 33.1B 3.38B 3.32B 134B	EV / Sales 2025 *	1.06x	EV / Sales 2026 *	0.98x
Free-Float	97.98%	Yield 2025 *	-	Yield 2026 *	-

Sector Update: Health Care Stocks Lower Late Afternoon	Mar. 12	MT
Myriad Genetics Shares Rise After Upgrade From Piper Sandler	Mar. 12	MT
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	Mar. 12	MT
Myriad Genetics And Gabbi To Work Together To Increase Access To Hereditary Cancer Risk Assessment Tools	Feb. 27	RE
Myriad Genetics, Inc. Provides Financial Guidance for 2025	Feb. 26	CI
UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	Feb. 25	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Underwhelming Economic Data, Renewed Trade Tensions	Feb. 25	MT
Myriad Genetics Appoints Sam Raha as Chief Executive	Feb. 25	MT
Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated	Feb. 25	MT
Myriad Genetics Appoints Sam Raha As President And CEO	Feb. 24	RE
Myriad Genetics, Inc., Q4 2024 Earnings Call, Feb 24, 2025	Feb. 24
Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Fourth Quarter Ended December 31, 2024	Feb. 24	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	Feb. 24	CI

Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	Mar. 12	MT
UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	Feb. 25	MT
Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	Dec. 09	MT
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	Nov. 18	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	24-09-19	MT

Myriad Genetics, Inc. Stock

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Valuation: Myriad Genetics, Inc.

Chart: Myriad Genetics, Inc.

Latest news: Myriad Genetics, Inc.

Last Transcript: Myriad Genetics, Inc.

Analysts' recommendations: Myriad Genetics, Inc.

Press Releases: Myriad Genetics, Inc.

News in other languages: Myriad Genetics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Myriad Genetics, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools	Feb. 27	GL
Myriad: Q4 Earnings Snapshot	Feb. 24	AQ
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth	Feb. 24	GL
Myriad Genetics Announces Senior Leadership Transition	Feb. 24	GL
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio	Feb. 24	GL

Eurobio Scientific : accord avec Myriad Genetics	24-05-08
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa	22-08-31
Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein	22-08-31
Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama	22-08-31
Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen	22-08-31

1 day	+3.81%
1 week	-1.08%
Current month	-6.15%
1 month	-30.84%
3 months	-30.21%
6 months	-63.50%
Current year	-26.55%

Manager	Title	Age	Since
Paul Diaz CEO	Chief Executive Officer	62	2020-08-12
Scott Leffler DFI	Director of Finance/CFO	50	2024-01-28
Thomas P. Slavin CTO	Chief Tech/Sci/R&D Officer	-	2021-06-15

Director	Title	Age	Since
S. Phanstiel CHM	Chairman	66	2020-03-22
Heiner Dreismann BRD	Director/Board Member	70	2010-06-09
Colleen Reitan BRD	Director/Board Member	65	2019-09-24

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MYRIAD GENETICS, INC.	+3.81%	-1.08%	-52.77%	-58.81%	919M
BIOMÉRIEUX	+1.60%	-0.78%	+14.00%	+24.59%	14.69B
LANTHEUS HOLDINGS, INC.	+1.82%	-4.93%	+68.98%	+102.73%	6.92B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.93%	-1.59%	-27.17%	+60.25%	6.46B
DIASORIN S.P.A.	-2.67%	-1.02%	-0.21%	-25.03%	5.54B
GUARDANT HEALTH, INC.	+5.54%	+9.08%	+133.48%	-11.11%	5.29B
AUTOBIO DIAGNOSTICS CO., LTD.	+2.49%	+1.05%	-33.00%	-11.52%	3.35B
ANDON HEALTH CO., LTD.	+2.07%	+0.66%	+4.28%	-28.90%	2.71B
VITROLIFE AB	+2.17%	+5.80%	-9.70%	-39.80%	2.39B
SANSURE BIOTECH INC.	+4.32%	+2.50%	+26.52%	-21.17%	2.04B
Average	+2.21%	+0.69%	+12.44%	-0.88%	5.03B
Weighted average by Cap.	+1.75%	+0.03%	+21.80%	+18.99%

	2025 *	2026 *
Net sales	850M 781M 752M 658M 1.22B 73.89B 1.35B 8.62B 3.27B 31.17B 3.19B 3.12B 126B	929M 854M 822M 719M 1.34B 80.75B 1.47B 9.42B 3.57B 34.06B 3.48B 3.41B 138B
Net income	-85.66M -78.74M -75.79M -66.32M -123M -7.45B -136M -869M -329M -3.14B -321M -315M -12.7B	-49.14M -45.17M -43.47M -38.04M -70.73M -4.27B -77.8M -498M -189M -1.8B -184M -180M -7.29B
Net Debt	-16.87M -15.51M -14.92M -13.06M -24.28M -1.47B -26.71M -171M -64.85M -619M -63.23M -61.95M -2.5B	-8.94M -8.22M -7.91M -6.92M -12.87M -777M -14.16M -90.68M -34.37M -328M -33.52M -32.84M -1.33B